Stay updated with breaking news from பிராட் மைல்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced ... apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
HUTCHMED Initiates a Japan Bridging Study to Support globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Share: – EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval – HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the European Medicines Agency ("EMA") has validated and accepted its marketing authorization application ("MAA") for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors ("NETs"). The EMA's validation confirms that the submission is sufficiently complete and that it is ready to commence the formal review process.
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million ... apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca mobilitytechzone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobilitytechzone.com Daily Mail and Mail on Sunday newspapers.
HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering mobilitytechzone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobilitytechzone.com Daily Mail and Mail on Sunday newspapers.
U.S. FDA Accepts Filing of HUTCHMED's NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors mobilitytechzone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobilitytechzone.com Daily Mail and Mail on Sunday newspapers.
HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong mobilitytechzone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobilitytechzone.com Daily Mail and Mail on Sunday newspapers.
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.